Skip to main content

Table 5 SAEs occurring in two or more patientsa

From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

SAE, n (%) Daclizumab 150 mg SC
(N = 410)
Any SAE 105 (26)
 MS relapse 47 (11)
 Increased hepatic enzyme 3 (<1)
 Pneumonia 3 (<1)
 Ulcerative colitis 3 (<1)
 Urinary tract infection 3 (<1)
 Bronchitis 2 (<1)
 Intervertebral disc disorder 2 (<1)
 Lower limb fracture 2 (<1)
 Lymphadenopathy 2 (<1)
 Urticariab 2 (<1)
  1. MS Multiple sclerosis, SAE Serious adverse event, SC Subcutaneous
  2. aSAEs in two or more patients by Medical Dictionary for Regulatory Activities Preferred Term
  3. bOther cutaneous SAEs are presented in Table 6